{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sevelamer+carbonate", "query": { "intervention": "Sevelamer carbonate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sevelamer+carbonate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T18:20:12.528Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03305471", "title": "DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "DS-2330b PIB", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sevelamer", "type": "DRUG" }, { "name": "DS-2330b Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2017-08-17", "completion_date": "2019-01-03", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 4, "location_summary": "Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Lakewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03305471" }, { "nct_id": "NCT01427907", "title": "Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Calcium acetate oral solution (COS)", "type": "DRUG" }, { "name": "Sevelamer carbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fresenius Medical Care North America", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-09", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2016-01-14", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 4, "location_summary": "New Haven, Connecticut • North Haven, Connecticut • New York, New York", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427907" }, { "nct_id": "NCT01493050", "title": "The Effects of Sevelamer Carbonate on Diabetic Nephropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Nephropathy" ], "interventions": [ { "name": "Sevelamer Carbonate", "type": "DRUG" }, { "name": "calcium carbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gary Striker", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2012-02", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-04-09", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01493050" }, { "nct_id": "NCT04278404", "title": "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronavirus Infection (COVID-19)", "Pulmonary Arterial Hypertension", "Urinary Tract Infections in Children", "Hypertension", "Pain", "Hyperphosphatemia", "Primary Hyperaldosteronism", "Edema", "Hypokalemia", "Heart Failure", "Hemophilia", "Menorrhagia", "Insomnia", "Pneumonia", "Skin Infection", "Arrythmia", "Asthma in Children", "Bronchopulmonary Dysplasia", "Adrenal Insufficiency", "Fibrinolysis; Hemorrhage", "Attention Deficit Hyperactivity Disorder", "Multisystem Inflammatory Syndrome in Children (MIS-C)", "Kawasaki Disease", "Coagulation Disorder", "Down Syndrome" ], "interventions": [ { "name": "The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "0 Years to 20 Years" }, "enrollment_count": 5000, "start_date": "2020-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278404" }, { "nct_id": "NCT01574326", "title": "An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperphosphatemia", "Chronic Kidney Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sevelamer carbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 101, "start_date": "2012-05", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01574326" }, { "nct_id": "NCT03824587", "title": "Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "Tenapanor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Phosphate Binder Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardelyx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 236, "start_date": "2019-02-28", "completion_date": "2019-07-17", "has_results": true, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 48, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Lynwood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03824587" }, { "nct_id": "NCT02965053", "title": "A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "EOS789", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Renvela", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chugai Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2016-12", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2018-09-13", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02965053" }, { "nct_id": "NCT00853242", "title": "Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Failure, Chronic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Genz-644470", "type": "DRUG" }, { "name": "Sevelamer carbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 349, "start_date": "2009-02", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2015-05-01", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 52, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853242" }, { "nct_id": "NCT01543958", "title": "Sevelamer for Reducing Endotoxemia and Immune Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Sevelamer carbonate", "type": "DRUG" }, { "name": "Sevelamer carbonate", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2011-11", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01543958" }, { "nct_id": "NCT03427125", "title": "A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "Tenapanor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sevelamer Carbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardelyx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1559, "start_date": "2018-01-08", "completion_date": "2020-02-27", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-09-23T18:20:12.528Z", "location_count": 2, "location_summary": "The Bronx, New York • Winston-Salem, North Carolina", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03427125" } ] }